Alexion top line up 26%, earnings up 24%, guidance raised

• Alexion Pharmaceuticals (NASDAQ:ALXN) Q3 results:
• Revenues: $1,588.7M (+25.8%); product sales: $1,588.3M (+25.7%).
• Key product sales: Soliris: $1,042.3 (+5.2%); Ultomiris: $289.3M (+221.8%); Strensiq: $189.4M (+22.7%); Andexxa: $38.9M; Kanuma: $28.4M (flat).
• Net income: $578.1M (+23.6%); non-GAAP net income: $726.8M (+14.3%); EPS: $2.62 (26.0%); non-GAAP EPS: $3.24 (+16.1%).
• Cash flow ops (9 mo.): $2,162.4 (+37.9%).
• 2020 guidance: Revenues: $5,900M-5,950M from $5,550M-5,600M; Soliris/Ultomiris sales: $5,000M-5,035M from $4,725M-4,755M; metabolic revenues: $835M-845M from $785M-800M; Andexxa sales: $65M-70M from $40M-45M; EPS: $1.78-2.13 from $0.96-1.30; non-GAAP EPS: $11.70-12.00 from $10.65-10.95.
• https://seekingalpha.com/news/3628039-alexion-top-line-up-26-earnings-up-24-guidance-raised